绝代双骄

第十三届哈尔滨朝鲜族民俗文化展演举行_我的网站

A |     (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。    中新网哈尔滨8月22日电 (记者 王琳)8月22日，以“民俗焕彩 同心筑梦”为主题的第十三届哈尔滨朝鲜族民俗文化展演在哈尔滨人民广场举行，以铸牢中华民族共同体意识为主线，展现朝鲜族民俗文化的独特魅力。                   8月22日，以“民俗焕彩 同心筑梦”为主题的第十三届哈尔滨朝鲜族民俗文化展演在哈尔滨人民广场举行，图为歌舞表演。　赵宇航 摄          　　本届展演将静态展陈与动态演绎有机融合，打造“可看、可尝、可参与”的文化盛宴。现场汇聚了朝鲜族歌舞、长鼓舞等文艺精品，特设交响乐与民乐专场，还呈现了传统婚礼与花甲礼等民俗仪式，彰显重礼崇德的人文精神。         　　此外，向市民和游客开放摔跤、象棋、掷柶等经典民俗竞技体验，结合巨型拌饭共制、打糕米酒品鉴及传统服饰展示，让非遗传承融入群众生活，多维度展现朝鲜族民俗文化的原生韵味与时代新意。         　　作为已连续举办十三届的本土文化品牌，哈尔滨朝鲜族民俗文化展演已成为展示民族文化魅力、汇聚城市文化活力的重要平台。本届展演内容设计更加丰富，活动形式更加鲜活，不仅让传统民俗走近群众、融入生活，也为各民族交往交流搭建了鲜活开放的窗口。         　　本次活动由哈尔滨市文化广电和旅游局主办，哈尔滨市民族宗教事务局支持，哈尔滨市朝鲜民族艺术馆、哈尔滨市朝鲜民族事业促进会承办，旨在宣传贯彻《中华人民共和国民族团结进步促进法》，从参与规模、活动品质到现场反响，各项表现均较往届有所提升。(完)                【编辑:刘阳禾】。

Current article:http://c5c.foujiongwenruapoumeizhan.buzz/list_ehu/lxy5.html

Published on:12:15:50